# OnCo record paper-emerald-1-lancet-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-emerald-1-lancet-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-emerald-1-lancet-2025" ;
  schema:name "EMERALD-1: durvalumab with or without bevacizumab added to transarterial chemoembolisation for embolisation-eligible hepatocellular carcinoma"@en ;
  schema:description "Adding durvalumab and bevacizumab to chemoembolisation lengthened the time to progression by about seven months in liver cancer suitable for embolisation, the first systemic combination to improve on chemoembolisation alone."@en ;
  schema:url <https://onco.cc/key-papers/paper-emerald-1-lancet-2025/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(24)02551-0>, <https://pubmed.ncbi.nlm.nih.gov/39798579/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(24)02551-0> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Sangro B, Kudo M, Erinjeri JP, et al." ;
  onco:cancers <https://onco.cc/cancers/hcc-intermediate/> ;
  onco:drugs <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/durvalumab/> ;
  onco:trials <https://onco.cc/trials/emerald-1/> ;
  onco:journals <https://onco.cc/journals/lancet/> .